Pulmocide is a biopharmaceutical company developing new medicines for difficult-to-treat respiratory diseases. Our current focus is on respiratory fungal infections, which can be serious and life-threatening. Pulmocide’s lead compound is a novel investigational inhaled antifungal agent (opelconazole) for the treatment of pulmonary aspergillosis, the most common fungal lung disease.
Inhaled opelconazole has been designed to be a potent inhaled antifungal agent to deliver and retain high concentrations of drug to the site of infection in the lung with minimal systemic exposure, in an effort to improve patient outcomes and reduce the potential for side effects and drug interactions. Opelconazole is currently undergoing evaluation in a phase 3 clinical trial for the treatment of patients with invasive pulmonary aspergillosis who are not responding to standard-of-care antifungal medicines.
www.pulmocide.com
